{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:12:38Z","timestamp":1786374758569,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.2459\/jcm.0b013e328334c7b9","type":"journal-article","created":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T08:52:55Z","timestamp":1283331175000},"page":"250-259","source":"Crossref","is-referenced-by-count":15,"title":["Safety of downstream high-dose tirofiban bolus among 1578 patients undergoing percutaneous coronary intervention: the Sant'ANna TIrofiban Safety study"],"prefix":"10.2459","volume":"11","author":[{"given":"Michele","family":"Schiariti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Saladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindo","family":"Missiroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Papalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Cuturello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Emilio","family":"Puddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210207","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(98)11086-3","article-title":"Platelet IIb-IIIa blockers","volume":"353","author":"Topol","year":"1999","journal-title":"Lancet"},{"key":"R2-5-20210207","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1053\/euhj.2002.3385","article-title":"Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute coronary syndromes of the European Society of Cardiology","volume":"23","author":"Bertrand","year":"2002","journal-title":"Eur Heart J"},{"key":"R3-5-20210207","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0735-1097(02)02336-7","article-title":"The ACC\/AHA 2002 guideline update of management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina)","volume":"40","author":"Braunwald","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R4-5-20210207","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/17425255.3.2.275","article-title":"Current strategies with high-dose tirofiban","volume":"3","author":"Mukherjee","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R5-5-20210207","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","article-title":"Comparison of two glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization","volume":"344","author":"Topol","year":"2001","journal-title":"N Engl J Med"},{"key":"R6-5-20210207","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","article-title":"Effect of platelet glycoprotein IIb\/IIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.","volume":"96","year":"1997","journal-title":"Circulation"},{"key":"R7-5-20210207","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0002-9149(01)02319-0","article-title":"Suboptimal early inhibition of platelets by treatment with tirofiban and implication for coronary interventions","volume":"89","author":"Kabbani","year":"2002","journal-title":"Am J Cardiol"},{"key":"R8-5-20210207","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0002-9149(02)02892-8","article-title":"Enhanced early inhibition of platelet aggregation with an increase bolus of tirofiban","volume":"90","author":"Schneider","year":"2002","journal-title":"Am J Cardiol"},{"key":"R9-5-20210207","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.amjcard.2004.03.026","article-title":"Comparison in patients having primary coronary angioplasty of abcximab versus tirofiban on recovery of left ventricular function","volume":"94","author":"Danzi","year":"2004","journal-title":"Am J Cardiol"},{"key":"R10-5-20210207","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ccd.10734","article-title":"Safety of high bolus dose of tirofiban in patients undergoing coronary stent placement","volume":"61","author":"Danzi","year":"2004","journal-title":"Cathet Cardiovasc Interv"},{"key":"R11-5-20210207","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jacc.2004.03.042","article-title":"The additive value of tirofiban with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE trial","volume":"44","author":"Valgimigli","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R12-5-20210207","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijcard.2005.03.025","article-title":"Downstream administration of a high-dose tirofiban bolus in high-risk patients with unstable angina undergoing early percutaneous coronary intervention","volume":"107","author":"Danzi","year":"2006","journal-title":"Int J Cardiol"},{"key":"R13-5-20210207","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jacc.2005.11.012","article-title":"Randomized comparison of upstream tirofiban versus downstream high dose tirofiban or abciximab on tissue level perfusion and troponin release in high risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial","volume":"47","author":"Bolognese","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R14-5-20210207","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00380-005-0870-4","article-title":"Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty","volume":"21","author":"Bilsel","year":"2006","journal-title":"Heart Vessels"},{"key":"R15-5-20210207","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijcard.2005.05.045","article-title":"Comparison of abciximab with \u2018high-dose\u2019 tirofiban in patients undergoing percutaneous coronary intervention","volume":"109","author":"Gunasekara","year":"2006","journal-title":"Int J Cardiol"},{"key":"R16-5-20210207","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ahj.2007.03.023","article-title":"Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial","volume":"154","author":"Valgimigli","year":"2007","journal-title":"Am Heart J"},{"key":"R17-5-20210207","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1001\/jama.299.15.joc80026","article-title":"Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTI-STRATEGY randomized trial","volume":"299","author":"Valgimigli","year":"2008","journal-title":"JAMA"},{"key":"R18-5-20210207","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/1097-0142(20010415)91:8+<1615::AID-CNCR1175>3.0.CO;2-L","article-title":"Artificial NN. Opening the black box","volume":"91","author":"Dayhoff","year":"2001","journal-title":"Cancer"},{"key":"R19-5-20210207","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/clinchem\/39.4.561","article-title":"Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine","volume":"39","author":"Zweig","year":"1993","journal-title":"Clin Chem"},{"key":"R20-5-20210207","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2307\/2223319","article-title":"Measurement of inequality of incomes","volume":"31","author":"Gini","year":"1921","journal-title":"Econ J"},{"key":"R22-5-20210207","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11096-004-2269-1","article-title":"Choice of GPIIb\/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in?","volume":"27","author":"Le Pen","year":"2005","journal-title":"Pharm World Sci"},{"key":"R23-5-20210207","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jacc.2009.01.053","article-title":"Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty","volume":"53","author":"De Luca","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R24-5-20210207","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2009.02.009","article-title":"The benefits of platelet glycoprotein IIb\/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?","volume":"53","author":"Brener","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R25-5-20210207","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0735-1097(99)00650-6","article-title":"Abciximab reduces mortality in diabetics following percutaneous coronary intervention","volume":"35","author":"Bhatt","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R26-5-20210207","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1161\/01.CIR.0000148956.93631.4D","article-title":", ISAR-SWEET Study Investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.","volume":"110","author":"Mehilli","year":"2004","journal-title":"Circulation"},{"key":"R27-5-20210207","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2459\/JCM.0b013e32832180d9","article-title":"Glycoprotein IIb\/IIIa inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the \u2018OPTIMIZE-IT\u2019 pilot randomized study","volume":"10","author":"Talarico","year":"2009","journal-title":"J Cardiovasc Med"},{"key":"R28-5-20210207","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0735-1097(01)01344-4","article-title":"ACC\/AHA Guidelines for percutaneous coronary intervention (revision of the 1993 PTCA Guidelines): executive summary.","volume":"37","author":"Smith","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"R30-5-20210207","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.amjcard.2007.05.048","article-title":"Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention","volume":"100","author":"Lotrionte","year":"2007","journal-title":"Am J Cardiol"},{"key":"R31-5-20210207","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"R32-5-20210207","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","article-title":"Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation"},{"key":"R33-5-20210207","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jacc.2009.06.021","article-title":"Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial","volume":"54","author":"Dangas","year":"2009","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01244665-201004000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:15:58Z","timestamp":1786371358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01244665-201004000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.2459\/jcm.0b013e328334c7b9","relation":{},"ISSN":["1558-2027"],"issn-type":[{"value":"1558-2027","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}